No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs) to delay the progression of AD (e.g., Biogen/Neurimmune’s aducanumab, Roche/MorphoSys’s gantenerumab, and others), and the first approved symptomatics to treat AD agitation—all within the next five years—will fundamentally alter the dynamics of this market, driven by clear need, strong market demand, and assumed premium pricing. Understanding neurologists’ preferences for and expectations from new therapeutics, counterpoised by payers’ receptivity to high-cost brands entering a highly underserved but heavily generic market, will be key for pharmaceutical companies developing new drugs or considering entering this wide-open arena.

Questions answered

  • What is the current state of coverage of key symptomatic therapies used to treat AD patients in the United States? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
  • How receptive are payers to late-phase DMTs and new brands in development for the management of AD agitation? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?
  • What actions can developers take to optimize market access?

Product description

U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Markets covered: United States

Primary research: Survey of 102 U.S. neurologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)

Key drugs covered: AChEIs, memantine, Namzaric, aducanumab, gantenerumab, antipsychotics, AVP-786, Rexulti

Content highlights

  • Reimbursement and contracting.
  • Access and prescribing.
  • Special topics.
  • Opportunities and challenges for emerging therapies.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Access & Reimbursement Alzheimer's Disease US May 2019

Author(s): Ruchita Kumar, Ph.D

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.

Related Reports

Alzheimer's Disease | Landscape & Forecast | Disease Landscape & Forecast

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open...

View Details

Alzheimer's Disease | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Alzheimer’s dise...

View Details

Alzheimer's Disease | Special Topics | Detailed, Expanded Analysis - Special Topics (US & EU)

Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to i...

View Details

Alzheimer's Disease | Unmet Need | Detailed, Expanded Analysis (US&EU) Early Alzheimer's Disease

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (

View Details